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Abstract
Background: It is well described that diabetes mellitus is a hypercoagulable state. It is also known that patients with
renal dysfunction have impaired platelet aggregation and function. It is not well described how renal dysfunction affects
the hypercoagulability associated with diabetes. This post-hoc sub-group analysis compares platelet function, clot
structure and thrombin generation time at baseline, and following enoxaparin exposure in three groups of subjects.
Methods: 30 total subjects were evaluated in the three groups: Group I: normal controls (n = 10), Group II: subjects
with renal dysfunction but without diabetes (n = 13), and Group III: subjects with concomitant diabetes and renal
dysfunction (n = 7). For each subject, platelet contractile force (PCF), clot elastic modulus (CEM) and thrombin
generation time (TGT) were simultaneously measured in whole blood at baseline, and following increasing enoxaparin
antifactor Xa activity exposure. The group means for each parameter were determined and compared using one-way
analysis of variance, with post-hoc Tukey-Kramer test.
Results: At baseline, subjects in Group III (diabetics with concomitant renal dysfunction) display significantly enhanced
platelet activity, as measured by PCF (p = 0.003) and CEM (p = 0.03), relative to the non-diabetic Groups I and II. Subjects
in Group II (renal dysfunction without diabetes) had significantly prolonged TGT values relative to controls when the
antifactor Xa activity concentration reached 0.5 (p = 0.007), 1.0 (p = 0.005) and 3.0 IU/mL (p < 0.0001), respectively.
There were no differences between Group II and Group III with respect to TGT at these antifactor Xa activity
concentrations. When the antifactor Xa activity concentration reached 3.0 IU/mL, Groups II and III formed significantly
less rigid blood clots (CEM p = 0.003) and also trended toward reduced PCF (p = 0.06) relative to Group I.
Conclusion: This hypothesis-generating sub-group analysis suggests that at baseline, patients with concomitant diabetes
and renal dysfunction have significantly enhanced platelet activity (PCF), and form more rigid blood clots (CEM)
compared to controls and subjects with renal dysfunction but no diabetes. This may suggest that the presence of renal
dysfunction does not ameliorate the hypercoagulable state associated with diabetes. Secondly, it appears that subjects
with renal dysfunction but without diabetes have an enhanced response to enoxaparin relative to controls.
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Diabetes mellitus is a hypercoagulable state [1]. It has
been demonstrated that patients with diabetes have
abnormally elevated markers of coagulation activation [2-
12], as well as increased risk of mortality from thrombosis
[13]. Indeed, virtually all Type II diabetics will die a
thrombotic death, whether its origin be cardiac, cerebrov-
ascular or peripheral vascular [14].
What is less clear is how the presence of renal dysfunction
affects the hypercoagulable state associated with diabetes.
This is an important question; given the fact that renal
dysfunction is so prevalent in patients with diabetes [15].
There is clinical and laboratory evidence that uremia asso-
ciated with renal dysfunction leads to platelet dysfunction
and altered hemostasis. [16-20]. However, we are una-
ware of any reports that suggest thrombotic risk decreases
in diabetics who develop renal dysfunction.
Our laboratory has developed a novel whole blood mon-
itoring assay that determines thrombin generation, plate-
let function and clot structure on a single sample of
patient blood. This assay provides a global assessment of
clotting function by reporting the markers platelet con-
tractile force (PCF), clot elastic modulus (CEM) and the
onset of thrombin generation as measured by thrombin
generation time (TGT). PCF is the force produced by
platelets during clot retraction, and is a novel measure of
platelet function during clotting; CEM reflects the struc-
tural integrity of the blood clot; and TGT is the speed at
which thrombin is produced in whole blood [21].
Changes in these parameters provide a detailed character-
ization of the hemostatic effect of various disease states
[22,23], antithrombotic and anticoagulant drugs
[21,24,25], and hemostatic agents [26] on platelet func-
tion and thrombin generation.
We report here findings of a hypothesis-generating sub-
group analysis that illustrate the effects of diabetes and
renal dysfunction on platelet function and thrombin gen-
eration time. In addition, we examined the potential
impacts of these disease states on the response to the com-
monly used low-molecular weight heparin enoxaparin.
Patients and Methods
This was a hypothesis-generating sub-group analysis of a
prospective, open-label, ex vivo study of enoxaparin in
patients with and without renal dysfunction [27]. The Vir-
ginia Commonwealth University (VCU) Institutional
Review Board approved this study prior to subject enroll-
ment, and this study was conducted in compliance with
the Declaration of Helsinki. In this study, a total of 30
subjects were evaluated: 10 healthy controls; 13 subjects
with renal dysfunction but without diabetes; and seven
patients with concomitant diabetes and renal dysfunction
(6 CKD and 1 ESRD).
All subjects were anticoagulant naïve, non-thrombosed,
and otherwise healthy. Subjects were admitted into this
study if they were > 18 years of age and provided written
informed consent. In addition, subjects with ESRD must
have received maintenance hemodialysis for at least 3
months through an arterio-venous fistula or graft. Sub-
jects were excluded from this investigation if they had any
of the following: active bleeding or thrombotic disorder;
pregnancy; recent trauma or surgery (< 7 days); cirrhosis
or other liver abnormality; hematocrit < 30%; active can-
cer; had received a blood transfusion within 1 week of
study enrollment; thrombocytopenia (platelets <
100,000/mL); documented history of antithrombin III,
protein C or protein S deficiency; concurrent use of anti-
coagulant or antiplatelet drug therapy. All subjects who
provided written informed consent and who met the
above criteria underwent screening evaluation, which
consisted of a routine physical exam and laboratory eval-
uation (basic metabolic panel, complete blood count
(CBC), international normalized ratio (INR), activated
partial thromboplastin time (aPTT), prothrombin time
(PT)).
Study Procedures
For each subject, blood was collected via aseptic veni-
puncture into four evacuated tubes containing 3.2%
sodium citrate. The blood was pooled and then aliquotted
into five separate samples, which were spiked with
increasing enoxaparin antifactor Xa activity concentra-
tions. Final enoxaparin antifactor Xa concentrations in the
respective aliquots were 0.0, 0.25, 0.50, 1.0, and 3.0 IU/
mL. For each aliquotted blood sample, analysis was per-
formed to determine the corresponding TGT, PCF and
CEM at each antifactor Xa activity concentration.
Specimen Processing and Analysis
Baseline chemistries (basic metabolic profile, CBC, PT,
aPTT, INR) and antifactor Xa concentrations were proc-
essed and analyzed at the VCU Health System Department
of Pathology. Plasma enoxaparin antifactor Xa activity
was measured using a validated, commercially available
chromogenic method (STA®  heparin colorimetric ana-
lyzer, Diagnostica Stago, Parsippany, NJ, USA), and the
results expressed as IU/mL. The lower limit of antifactor
Xa detection for this assay was 0.05 IU/mL; the coefficient
of variation (CV) was ± 3%. Whole blood samples were
analyzed for TGT, PCF and CEM at the VCU Coagulation
Special Studies Laboratory. The TGT, PCF and CEM for
each aliquotted whole blood sample were simultaneously
measured using the Hemodyne Hemostasis Analysis Sys-
tem™ (Hemodyne, Inc., Richmond, VA, USA) using a pre-
viously published, validated method [27]. All samples
were run in duplicate. The CV for this assay was ± 7%.Thrombosis Journal 2005, 3:3 http://www.thrombosisjournal.com/content/3/1/3
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Table 1: Baseline Subject Demographics
Group I Group II Group III
Parameter Controls (n = 10) Renal Dysfunction (n = 13) Diabetes and Renal Dysfunction (n = 7) P-value
Age [mean (S.D.)] 40.5 (9.6) 46.5 (15.0) 45.1 (11.1) NS
Race [number (%)]
Caucasian 5 (50) 1 (8) 0
Black 3 (30) 12 (92) 6 (86) 0.02§
Other 2 (20) 0 1 (14)
Sex [number (%)]
Male 5 (50) 7 (54) 3 (43) NS
Female 5 (50) 6 (46) 4 (57)
Weight
[mean kg (S.D.)] 75.0 (13.4) 83.9 (23.1) 86.0 (25.0) NS
CAD [number (%)]
Yes 1 (10) 2 (15) 3 (43) NS
No 9 (90) 11 (85) 4 (57)
NS – Not significant
§ Chi-square test for group homogeneity significantly different
Table 2: Mean (S.D.) Platelet Contractile Force, Clot Elastic Modulus and Thrombin Generation Time at Baseline and Following 
Increasing Enoxaparin Antifactor Xa Activity
Group I Group II Group III
Antifactor Xa Activity Controls (n = 10) Renal Dysfunction (n = 13) Diabetes and Renal Dysfunction (n = 7) P-value
Baseline
PCF† 8.5 (1.4) 9.8 (1.5) 12.0 (2.9)* 0.003
CEM‡ 23.2 (5.4) 29.0 (9.5) 37.3 (15.5)* 0.03
TGT§ 222.0 (60.3) 235.4 (53.2) 270.0 (52.0) NS
0.25 IU/mL
PCF 7.0 (1.8) 7.5 (1.6) 8.8 (2.9) NS
CEM 21.1 (4.1) 22.6 (4.1) 24.6 (7.1) NS
TGT 273.0 (68.5) 327.7 (70.8) 325.7 (76.3) NS
0.50 IU/mL
PCF 5.5 (1.9) 5.6 (1.8) 6.3 (2.4) NS
CEM 17.2 (5.1) 19.1 (4.4) 19.4 (5.0) NS
TGT 318.0 (68.1) 440.0 (97.5)* 420.0 (86.6) 0.007
1.0 IU/mL
PCF 3.6 (1.7) 3.0 (1.7) 4.0 (2.1) NS
CEM 11.9 (4.5) 10.0 (4.6) 12.9 (6.1) NS
TGT 423.0 (128.4) 588.5 (96.0)* 552.9 (114.7) 0.005
3.0 IU/mL
PCF 1.5 (1.3) 0.6 (0.2) 1.0 (0.9) 0.06
CEM 4.8 (4.4)* 0.8 (0.8) 0.9 (0.8) 0.003
TGT 780.0 (317.5) 1200.0 (0)* 1200.0 (0)* < 0.0001
† PCF – Kdynes, ‡ CEM – Kdynes/cm2,§TGT – seconds
NS – not significant
* Statistically significantThrombosis Journal 2005, 3:3 http://www.thrombosisjournal.com/content/3/1/3
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Statistical Analysis
All statistical analyses were performed using JMP statisti-
cal software version 5.1 (SAS Institute, Cary, NC, USA).
The data were presented based on subject group assign-
ment, as Group I: Control; Group II: subjects with renal
dysfunction but without diabetes; and Group III: subjects
with concomitant diabetes and renal dysfunction.
Descriptive statistics characterized the group demographic
data One-way analysis of variance (ANOVA) assessed for
intergroup differences in demographic data, and mean
PCF, CEM and TGT at baseline and at each spiked enoxa-
parin antifactor Xa activity concentration for each of the
three groups. If intergroup differences were found to be
statistically significant, a post-hoc Tukey-Kramer test was
used to differentiate which groups were statistically differ-
ent. The level of significance for all statistical tests was p <
0.05.
Results
Thirty subjects completed this study as described above.
There were no adverse reactions or dropouts from the
study. Table 1 details the subject demographics. Other
than differences in the racial makeup of the groups, the
groups were similar with respect to age, sex, weight and
presence of coronary artery disease (CAD).
Baseline Platelet Function, Clot Structure and Thrombin 
Generation Time
The top panel of Table 2 details the baseline PCF, CEM
and TGT in Groups I, II and III. Group III (concomitant
diabetes and renal dysfunction) exhibited significantly
greater platelet activity, as measured by PCF (p = 0.003)
and CEM (p = 0.03), relative to the non-diabetic groups I
and II. The reported TGT was not significantly different
between groups at baseline.
Comparative Platelet Function, Clot Structure and 
Thrombin Generation Times Following Increasing 
Enoxaparin Antifactor Xa Activity Concentrations
As the spiked ex vivo enoxaparin antifactor Xa activity con-
centration increased, there were corresponding changes in
PCF, CEM and TGT (Table 2). As expected, there was an
inverse relationship between increasing enoxaparin anti-
factor Xa activity and platelet function (i.e., PCF) and clot
structure (i.e., CEM) in all three groups. Conversely, there
was a direct relationship between TGT prolongation and
increasing enoxaparin antifactor Xa activity in the groups.
The PCF and CEM were not statistically different between
groups at antifactor Xa activity concentrations of 0.25, 0.5
or 1.0 IU/mL. However, when the antifactor Xa activity
concentration reached 3.0 IU/mL, Group I (controls) had
significantly higher CEM (p = 0.003) relative to the two
groups with renal dysfunction. There was also a trend of
greater PCF in Group I relative to the other groups.
The TGT was significantly prolonged in Group II (renal
dysfunction without diabetes) relative to Group I (con-
trols) at enoxaparin antifactor Xa activity concentrations
of 0.5 (p = 0.07), 1.0 (p = 0.005) and 3.0 IU/mL (p <
0.0001), respectively. There were no statistical differences
between Groups II and III (concomitant diabetes and
renal dysfunction) at these antifactor Xa activity
concentrations.
Discussion
This was a hypothesis-generating sub-group analysis per-
formed to assess the pro-coagulant effect of diabetes on
the platelet function in patients with CKD. To our knowl-
edge, this is the first study to demonstrate that at baseline,
diabetic patients with renal dysfunction have elevated
platelet activity. Our review of the literature fails to iden-
tify prior studies of platelet function specifically per-
formed in diabetics with renal dysfunction. Given the
apparently divergent effects of hyperglycemia and uremia
on platelet function, one might hypothesize that
depressed platelet function due to uremia may be partially
or completely reversed by the enhanced effects of diabe-
tes. At baseline, this appears to be the case. The presence
of diabetes increases platelet forces, vis-à-vis PCF and
results in greater clot strength, vis-à-vis CEM, compared to
the other non-diabetic groups I and II. However, despite
the increased platelet activity in diabetics with renal dys-
function noted at baseline, there were no differences in
TGT between groups.
Previous studies of platelet function in diabetes or uremia
have primarily involved measurement of platelet aggrega-
tion. Enhanced platelet aggregation has been demon-
strated with diabetes [3,29,30] and decreased platelet
aggregation has been identified in uremia [31-35]. Previ-
ous studies of PCF noted enhanced function in diabetes
[23], but normal values in chronic uremia [36]. These
studies are consistent with the current findings. The diver-
gence between aggregation results and PCF findings
centers around the fact that one assay (platelet aggrega-
tion) is performed with minimal platelet activation and
the other (PCF) under conditions of maximal platelet acti-
vation (i.e., platelets in the presence of thrombin).
Thrombin is such a profound agonist of platelet function
that subtle influences noted by platelet aggregation stud-
ies are simply overwhelmed. An example of this effect can
be seen with the effects of IIb/IIIa blockade on platelet
aggregation and PCF. The concentrations of IIb/IIIa block-
ing agents (e.g., abciximab, tirofiban) required to block
PCF production are an order of magnitude higher than
those required to suppress platelet aggregation [24].
The data from this analysis, although limited by the rela-
tively small sample size, suggests that there is a "counter-
balancing" effect of renal dysfunction and diabetes withThrombosis Journal 2005, 3:3 http://www.thrombosisjournal.com/content/3/1/3
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respect to platelet function and thrombin generation
time. This is borne out in Table 2. For example, subjects in
Group II (renal dysfunction but without diabetes) have
the greatest prolongations in TGT, compared to the other
groups, following increasing antifactor Xa activity. How-
ever, Group III (renal dysfunction with diabetes) subjects
tend to have a blunted TGT prolongation, though not sig-
nificantly different compared to Group II. One could
argue that given a larger sample size, potential differences
may be detected between Groups II and III. Our findings
should at least caution against assuming the presence of
an "auto" anticoagulant or "auto" antiplatelet effect of
uremia in patients with concomitant diabetes.
There are important limitations to these findings. First,
this study was a sub-group analysis not designed a priori to
detect these differences. Indeed, these differences were
detected on data analysis and thought to be important
hypothesis-generating data. Secondly, the groups pre-
sented were quite heterogeneous, both in terms of num-
bers and underlying disease states. That is, there were
control patients with neither diabetes nor renal dysfunc-
tion, there were patients with solely renal dysfunction but
no diabetes, and there were patients with concomitant
diabetes and renal dysfunction. A more appropriate way
to study the effects of diabetes and renal dysfunction on
platelet activity and thrombin generation time is prospec-
tively using four study groups: 1) non-diabetics without
CKD; 2) non-diabetics with CKD; 3) diabetics without
CKD; and 4) diabetics with CKD. This study design would
more appropriately describe the effect of diabetes on ure-
mic platelets. Moreover, this would allow for greater sta-
tistically analysis using a two-way ANOVA test, that could
detect an interaction between the concomitant disease
states on altered platelet function. Nevertheless, these data
are compelling enough to develop a hypothesis for further
study.
Conclusion
In conclusion, we report hypothesis-generating findings
that suggest that at baseline subjects with concomitant
diabetes and renal dysfunction have increased platelet
activity relative to healthy controls and patients with renal
dysfunction but no concomitant diabetes. This may sug-
gest that the presence of uremia does not completely
ameliorate the hypercoagulable effect of diabetes. Sec-
ondly, it appears that subjects with renal dysfunction but
without concomitant diabetes have an enhanced response
to enoxaparin compared to the controls, as measured by
TGT. Further large-scale studies are warranted to further
characterize the effects and interactions of diabetes and
renal dysfunction on platelet function.
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